Transaction #26663 · Form 4 · 0001193125-26-001123
Phathom Pharmaceuticals, Inc. · Stock award · Stock Option (Right to Buy)
Phathom Pharmaceuticals, Inc. · Transacted January 2, 2026 · Filed January 2, 2026
What does this filing report?
An SEC Form 4 filing for Phathom Pharmaceuticals, Inc. records a stock award involving Stock Option (Right to Buy) on January 2, 2026. The reported quantity was 42,848. The filing date is January 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001783183
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 42,848
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 42,848
- Ownership description
- Not reported
- SEC acceptance time
- Jan 2, 2026, 5:42 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Narula Sanjeev ↗
Chief Financial & Bus. Officer
CIK 0001820590
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 42,848
- Conversion / exercise price
- 15.71
- Exercise date
- Not reported
- Expiration date
- January 1, 2036
Filing footnotes & remarks
- F1
- Represents restricted stock units ("RSUs") granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
- F2
- 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.